Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion

Morten Persson; Jacob Madsen; Søren Østergaard; Mette Munk Jensen; Jesper Tranekjær Jørgensen; Karina Juhl; Charlotte Lehmann; Michael Ploug; Andreas Kjaer

doi:10.2967/jnumed.110.083386

Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion

Morten Persson, Jacob Madsen, Søren Østergaard, Mette Munk Jensen, Jesper Tranekjær Jørgensen, Karina Juhl, Charlotte Lehmann, Michael Ploug, Andreas Kjaer

Department of Clinical Physiology and Nuclear Medicine

79 Citations (Scopus)

Abstract

Expression levels of the urokinase-type plasminogen activator receptor (uPAR) represent an established biomarker for poor prognosis in a variety of human cancers. The objective of the present study was to explore whether noninvasive PET can be used to perform a quantitative assessment of expression levels of uPAR across different human cancer xenograft models in mice and to illustrate the clinical potential of uPAR PET in future settings for individualized therapy.

Original language	English
Journal	Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume	53
Issue number	1
Pages (from-to)	138-45
Number of pages	8
DOIs	https://doi.org/10.2967/jnumed.110.083386
Publication status	Published - 2012

Access to Document

10.2967/jnumed.110.083386

Cite this

Persson, M., Madsen, J., Østergaard, S., Jensen, M. M., Jørgensen, J. T., Juhl, K., Lehmann, C., Ploug, M., & Kjaer, A. (2012). Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53(1), 138-45. https://doi.org/10.2967/jnumed.110.083386

Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. / Persson, Morten; Madsen, Jacob; Østergaard, Søren et al.
In: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 53, No. 1, 2012, p. 138-45.

Research output: Contribution to journal › Journal article › Research › peer-review

Persson, M, Madsen, J, Østergaard, S, Jensen, MM, Jørgensen, JT, Juhl, K, Lehmann, C, Ploug, M & Kjaer, A 2012, 'Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 53, no. 1, pp. 138-45. https://doi.org/10.2967/jnumed.110.083386

@article{060b2c7e0db14dcca28cedf846897278,

title = "Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion",

abstract = "Expression levels of the urokinase-type plasminogen activator receptor (uPAR) represent an established biomarker for poor prognosis in a variety of human cancers. The objective of the present study was to explore whether noninvasive PET can be used to perform a quantitative assessment of expression levels of uPAR across different human cancer xenograft models in mice and to illustrate the clinical potential of uPAR PET in future settings for individualized therapy.",

author = "Morten Persson and Jacob Madsen and S{\o}ren {\O}stergaard and Jensen, \{Mette Munk\} and J{\o}rgensen, \{Jesper Tranekj{\ae}r\} and Karina Juhl and Charlotte Lehmann and Michael Ploug and Andreas Kjaer",

year = "2012",

doi = "10.2967/jnumed.110.083386",

language = "English",

volume = "53",

pages = "138--45",

journal = "Journal of nuclear medicine : official publication, Society of Nuclear Medicine",

issn = "1535-5667",

publisher = "Society of Nuclear Medicine Inc.",

number = "1",

}

TY - JOUR

T1 - Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion

AU - Persson, Morten

AU - Madsen, Jacob

AU - Østergaard, Søren

AU - Jensen, Mette Munk

AU - Jørgensen, Jesper Tranekjær

AU - Juhl, Karina

AU - Lehmann, Charlotte

AU - Ploug, Michael

AU - Kjaer, Andreas

PY - 2012

Y1 - 2012

N2 - Expression levels of the urokinase-type plasminogen activator receptor (uPAR) represent an established biomarker for poor prognosis in a variety of human cancers. The objective of the present study was to explore whether noninvasive PET can be used to perform a quantitative assessment of expression levels of uPAR across different human cancer xenograft models in mice and to illustrate the clinical potential of uPAR PET in future settings for individualized therapy.

AB - Expression levels of the urokinase-type plasminogen activator receptor (uPAR) represent an established biomarker for poor prognosis in a variety of human cancers. The objective of the present study was to explore whether noninvasive PET can be used to perform a quantitative assessment of expression levels of uPAR across different human cancer xenograft models in mice and to illustrate the clinical potential of uPAR PET in future settings for individualized therapy.

UR - https://www.scopus.com/pages/publications/84855392303

U2 - 10.2967/jnumed.110.083386

DO - 10.2967/jnumed.110.083386

M3 - Journal article

C2 - 22213823

SN - 1535-5667

SN - 2159-662X

VL - 53

SP - 138

EP - 145

JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine

JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine

IS - 1

ER -

Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion

Abstract

Access to Document

Other files and links

Fingerprint

Cite this